The treatment success rate for patients with multidrug-resistant tuberculosis (MDR-TB) in India is projected to remain constant at 48% from 2024 to 2028. In 2023, the success rate was also 48%, implying no year-on-year improvement in upcoming years. The absence of variation indicates a stagnant trend with a CAGR of 0% over the forecasted period. This static forecast could reflect ongoing challenges in addressing MDR-TB effectively in India.

Future trends to watch for include:

Potential impacts of new treatment regimens and drug innovations on success rates.
Enhanced healthcare policies and infrastructure to combat drug resistance.
Community health initiatives aimed at improving early diagnosis and adherence to treatment.